XFOR Historical Balance Sheet

XFOR Stock

USD 0.51 0 0.39%

Trend analysis of X4 Pharmaceuticals balance sheet accounts such as Total Assets of 102.4 M, Short Long Term Debt Total of 70.4 M, Other Current Liabilities of 15.5 M or Total Current Liabilities of 13.7 M provides information on X4 Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of X4 Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using X4 Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining X4 Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether X4 Pharmaceuticals is a good buy for the upcoming year.

X4 Pharmaceuticals Inventory

(638,685)

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

About XFOR Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of X4 Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. X4 Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of X4 Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which XFOR currently owns. An asset can also be divided into two categories, current and non-current.

X4 Pharmaceuticals Balance Sheet Chart

At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 02/17/2025, Other Stockholder Equity is likely to grow to about 638.7 M, while Total Current Liabilities is likely to drop slightly above 13.7 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Property Plant Equipment

Add Fundamental

Total Assets

Total assets refers to the total amount of X4 Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in X4 Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on X4 Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of X4 Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from X4 Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 02/17/2025, Other Stockholder Equity is likely to grow to about 638.7 M, while Total Current Liabilities is likely to drop slightly above 13.7 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	38.4M	58.3M	67.0M	70.4M
Total Assets	155.6M	147.3M	169.3M	102.4M

Short Long Term Debt Total Total Assets

X4 Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab
Total Assets		0.8	0.74	0.79	0.93	0.79	0.32	-0.85	-0.83	0.77	0.99	0.9	0.74	0.99	-0.5	0.75	0.62	0.42	0.79	0.8	0.53	0.81	0.99	-0.46	0.68	0.63
Short Long Term Debt Total	0.8		0.96	0.84	0.61	0.77	0.19	-0.45	-0.95	0.97	0.74	0.76	0.63	0.77	-0.79	0.92	0.92	0.82	0.97	0.97	0.72	0.82	0.78	-0.35	0.92	0.86
Other Current Liab	0.74	0.96		0.85	0.52	0.68	0.01	-0.4	-0.94	0.97	0.68	0.69	0.49	0.72	-0.71	0.9	0.94	0.87	0.93	0.95	0.77	0.74	0.73	-0.32	0.95	0.92
Total Current Liabilities	0.79	0.84	0.85		0.5	0.75	0.08	-0.43	-0.9	0.89	0.73	0.69	0.47	0.78	-0.72	0.85	0.78	0.77	0.85	0.85	0.92	0.82	0.79	-0.14	0.84	0.84
Total Stockholder Equity	0.93	0.61	0.52	0.5		0.65	0.45	-0.95	-0.64	0.55	0.95	0.83	0.74	0.93	-0.23	0.55	0.39	0.1	0.62	0.62	0.17	0.64	0.92	-0.52	0.46	0.39
Property Plant And Equipment Net	0.79	0.77	0.68	0.75	0.65		0.03	-0.5	-0.78	0.7	0.72	0.89	0.72	0.72	-0.7	0.76	0.51	0.5	0.78	0.77	0.6	0.99	0.73	-0.17	0.56	0.52
Current Deferred Revenue	0.32	0.19	0.01	0.08	0.45	0.03		-0.49	-0.19	0.23	0.41	0.04	0.29	0.39	-0.07	0.19	0.16	-0.11	0.28	0.21	-0.17	0.04	0.39	-0.15	0.2	0.16
Net Debt	-0.85	-0.45	-0.4	-0.43	-0.95	-0.5	-0.49		0.53	-0.46	-0.92	-0.69	-0.59	-0.88	0.11	-0.46	-0.27	-0.02	-0.49	-0.49	-0.1	-0.48	-0.87	0.37	-0.38	-0.35
Retained Earnings	-0.83	-0.95	-0.94	-0.9	-0.64	-0.78	-0.19	0.53		-0.96	-0.79	-0.73	-0.52	-0.82	0.69	-0.96	-0.88	-0.74	-0.98	-0.98	-0.73	-0.83	-0.83	0.32	-0.93	-0.89
Accounts Payable	0.77	0.97	0.97	0.89	0.55	0.7	0.23	-0.46	-0.96		0.73	0.65	0.48	0.77	-0.76	0.95	0.95	0.86	0.97	0.97	0.77	0.75	0.78	-0.26	0.98	0.95
Cash	0.99	0.74	0.68	0.73	0.95	0.72	0.41	-0.92	-0.79	0.73		0.85	0.7	1.0	-0.42	0.71	0.57	0.34	0.75	0.75	0.44	0.74	0.99	-0.43	0.64	0.6
Non Current Assets Total	0.9	0.76	0.69	0.69	0.83	0.89	0.04	-0.69	-0.73	0.65	0.85		0.85	0.85	-0.56	0.64	0.5	0.41	0.7	0.71	0.5	0.89	0.85	-0.39	0.53	0.46
Non Currrent Assets Other	0.74	0.63	0.49	0.47	0.74	0.72	0.29	-0.59	-0.52	0.48	0.7	0.85		0.69	-0.46	0.4	0.34	0.24	0.55	0.53	0.27	0.7	0.68	-0.25	0.33	0.24
Cash And Short Term Investments	0.99	0.77	0.72	0.78	0.93	0.72	0.39	-0.88	-0.82	0.77	1.0	0.85	0.69		-0.45	0.74	0.62	0.4	0.78	0.78	0.51	0.76	1.0	-0.46	0.69	0.64
Net Receivables	-0.5	-0.79	-0.71	-0.72	-0.23	-0.7	-0.07	0.11	0.69	-0.76	-0.42	-0.56	-0.46	-0.45		-0.72	-0.72	-0.84	-0.74	-0.7	-0.78	-0.73	-0.46	0.04	-0.68	-0.65
Common Stock Total Equity	0.75	0.92	0.9	0.85	0.55	0.76	0.19	-0.46	-0.96	0.95	0.71	0.64	0.4	0.74	-0.72		0.86	0.76	0.96	0.96	0.7	0.8	0.75	-0.2	0.9	0.87
Common Stock Shares Outstanding	0.62	0.92	0.94	0.78	0.39	0.51	0.16	-0.27	-0.88	0.95	0.57	0.5	0.34	0.62	-0.72	0.86		0.88	0.91	0.91	0.74	0.6	0.63	-0.4	0.98	0.94
Non Current Liabilities Total	0.42	0.82	0.87	0.77	0.1	0.5	-0.11	-0.02	-0.74	0.86	0.34	0.41	0.24	0.4	-0.84	0.76	0.88		0.76	0.77	0.86	0.56	0.41	-0.04	0.86	0.87
Other Current Assets	0.79	0.97	0.93	0.85	0.62	0.78	0.28	-0.49	-0.98	0.97	0.75	0.7	0.55	0.78	-0.74	0.96	0.91	0.76		0.99	0.68	0.82	0.79	-0.33	0.93	0.89
Other Stockholder Equity	0.8	0.97	0.95	0.85	0.62	0.77	0.21	-0.49	-0.98	0.97	0.75	0.71	0.53	0.78	-0.7	0.96	0.91	0.77	0.99		0.69	0.82	0.79	-0.34	0.94	0.9
Total Liab	0.53	0.72	0.77	0.92	0.17	0.6	-0.17	-0.1	-0.73	0.77	0.44	0.5	0.27	0.51	-0.78	0.7	0.74	0.86	0.68	0.69		0.68	0.52	-0.03	0.75	0.77
Property Plant And Equipment Gross	0.81	0.82	0.74	0.82	0.64	0.99	0.04	-0.48	-0.83	0.75	0.74	0.89	0.7	0.76	-0.73	0.8	0.6	0.56	0.82	0.82	0.68		0.77	-0.23	0.63	0.59
Total Current Assets	0.99	0.78	0.73	0.79	0.92	0.73	0.39	-0.87	-0.83	0.78	0.99	0.85	0.68	1.0	-0.46	0.75	0.63	0.41	0.79	0.79	0.52	0.77		-0.46	0.7	0.65
Short Term Debt	-0.46	-0.35	-0.32	-0.14	-0.52	-0.17	-0.15	0.37	0.32	-0.26	-0.43	-0.39	-0.25	-0.46	0.04	-0.2	-0.4	-0.04	-0.33	-0.34	-0.03	-0.23	-0.46		-0.33	-0.23
Common Stock	0.68	0.92	0.95	0.84	0.46	0.56	0.2	-0.38	-0.93	0.98	0.64	0.53	0.33	0.69	-0.68	0.9	0.98	0.86	0.93	0.94	0.75	0.63	0.7	-0.33		0.98
Other Liab	0.63	0.86	0.92	0.84	0.39	0.52	0.16	-0.35	-0.89	0.95	0.6	0.46	0.24	0.64	-0.65	0.87	0.94	0.87	0.89	0.9	0.77	0.59	0.65	-0.23	0.98

Click cells to compare fundamentals

X4 Pharmaceuticals Account Relationship Matchups

X4 Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	122.9M	117.2M	155.6M	147.3M	169.3M	102.4M
Short Long Term Debt Total	38.4M	39.8M	38.4M	58.3M	67.0M	70.4M
Other Current Liab	7.2M	6.8M	10.8M	12.8M	14.7M	15.5M
Total Current Liabilities	11.9M	14.0M	22.3M	22.9M	26.3M	13.7M
Total Stockholder Equity	72.8M	64.4M	74.1M	51.1M	58.8M	46.6M
Property Plant And Equipment Net	9.2M	10.2M	8.3M	6.4M	7.4M	4.7M
Net Debt	(40.3M)	(42.0M)	(83.3M)	(40.9M)	(36.8M)	(38.7M)
Retained Earnings	(194.2M)	(282.9M)	(376.7M)	(477.9M)	(430.1M)	(408.6M)
Accounts Payable	3.1M	4.3M	7.8M	8.9M	10.3M	10.8M
Cash	78.7M	81.8M	121.7M	99.2M	114.1M	76.4M
Non Current Assets Total	39.6M	29.3M	26.9M	25.2M	29.0M	19.2M
Non Currrent Assets Other	3.3M	1.7M	1.2M	1.4M	1.7M	1.6M
Cash And Short Term Investments	78.7M	81.8M	121.7M	114.2M	131.3M	78.2M
Net Receivables	917K	747K	1.2M	562K	505.8K	480.5K
Common Stock Shares Outstanding	20.1M	25.7M	63.5M	177.8M	204.5M	214.7M
Liabilities And Stockholders Equity	122.9M	117.2M	155.6M	147.3M	169.3M	102.4M
Non Current Liabilities Total	38.1M	38.7M	59.2M	73.3M	84.3M	88.5M
Other Current Assets	3.7M	5.3M	5.8M	7.3M	8.4M	8.8M
Other Stockholder Equity	267.1M	347.4M	450.8M	529.0M	608.3M	638.7M
Total Liab	50.1M	52.8M	81.5M	96.2M	110.6M	55.9M
Property Plant And Equipment Gross	9.2M	10.2M	8.3M	8.0M	9.2M	4.9M
Total Current Assets	83.3M	87.9M	128.7M	122.1M	140.4M	83.3M
Short Term Debt	1.6M	2.9M	3.7M	1.1M	989.1K	1.9M
Other Liab	16K	462K	826K	23.3M	26.8M	28.1M
Net Tangible Assets	102.1M	45.7M	47.1M	56.7M	65.2M	68.5M
Long Term Debt	33.2M	33.1M	32.3M	54.6M	62.8M	65.9M
Non Current Liabilities Other	462K	826K	3.6M	432K	496.8K	748K
Property Plant Equipment	2.4M	9.2M	10.2M	1.1M	1.3M	1.2M
Capital Surpluse	156.6M	261.4M	267.1M	450.8M	518.4M	283.1M
Net Invested Capital	106.0M	98.3M	107.7M	105.7M	121.5M	104.9M
Net Working Capital	71.4M	73.9M	106.4M	99.2M	114.1M	89.4M

Pair Trading with X4 Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against XFOR Stock

0.57	AMCCF	Amcor plc	Pair Corr
0.54	JNJ	Johnson Johnson	Pair Corr
0.51	INVA	Innoviva	Pair Corr
0.51	APVO	Aptevo Therapeutics	Pair Corr
0.37	AMGN	Amgen Inc	Pair Corr

The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.

The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for XFOR Stock Analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

XFOR Historical Balance Sheet

X4 Pharmaceuticals Inventory

(638,685)

About XFOR Balance Sheet Analysis

X4 Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

X4 Pharmaceuticals balance sheet Correlations

X4 Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

X4 Pharmaceuticals balance sheet Accounts

Pair Trading with X4 Pharmaceuticals

Moving against XFOR Stock

Additional Tools for XFOR Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net

Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Accounts Payable	- 0.96	Retained Earnings
Net Debt	- 0.95	Total Stockholder Equity
Retained Earnings	- 0.95	Short Long Term Debt Total